EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Breast surgery after neoadjuvant systemic therapy

Kate R Pawloski, Andrea V Barrio

Translational Breast Cancer Research · 2024-04 · 5 · 13-13

DOI: 10.21037/tbcr-23-50 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Translational Breast Cancer Research, 2024-04. Verfasst von Kate R Pawloski und 1 weiteren Autor:innen. Beteiligte Einrichtung: Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For patients with operable breast cancer, neoadjuvant systemic therapy (NST) can be used to downstage the primary tumor in the breast and to facilitate breast-conserving surgery (BCS) in patients with large tumors who desire breast conservation. Rates of breast pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) are highest in patients with triple-negative and human epidermal growth factor receptor 2 (HER2) positive (HER2+) disease; however, achieving pCR is not necessary for successful downstaging and avoidance of mastectomy, and rates of conversion to BCS-eligibility are high across all receptor subtypes. Neoadjuvant endocrine therapy (NET) can be used instead of NAC in postmenopausal patients with hormone receptor positive (HR+)/HER2 negative (HER2-) breast cancer to downstage the breast, particularly when the patient has no clear indication for systemic chemotherapy, but desires breast conservation. In patients treated with NET, rates of conversion to BCS-eligibility are similar to rates observed with NAC. The oncologic safety of BCS after NAC and NET has been established in prospective trials, and local recurrence (LR) rates are acceptably low provided negative surgical margins can be obtained. Investigation is under way to determine the feasibility and safety of omitting breast surgery in patients with responsive subtypes who have no residual invasive or in situ disease identified on post-treatment tumor bed biopsies; however, the significant risk of missing residual disease-which may impact selection of adjuvant systemic therapy-may preclude future adoption of this approach.

Schlagwörter

Stichwörter der Autor:innen

Neoadjuvant chemotherapy (NAC)breast-conserving surgery (BCS)downstagingneoadjuvant endocrine therapy (NET)

Autor:innen und Institutionen

  • Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Pawloski, K. R., & Barrio, A. V. (2024). Breast surgery after neoadjuvant systemic therapy. Translational Breast Cancer Research, 5, 13-13. https://doi.org/10.21037/tbcr-23-50

Vancouver

Pawloski KR, Barrio AV. Breast surgery after neoadjuvant systemic therapy. Translational Breast Cancer Research. 2024;5:13-13. doi:10.21037/tbcr-23-50

BibTeX
@article{Pawloski2024,
  author = {Pawloski, Kate R and Barrio, Andrea V},
  title = {Breast surgery after neoadjuvant systemic therapy},
  journal = {Translational Breast Cancer Research},
  year = {2024},
  volume = {5},
  pages = {13--13},
  doi = {10.21037/tbcr-23-50}
}
Kostenlos starten →